- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07279571
GYN-AIDE: Gynecologic Oncology Navigation Through AI-Driven Education
May 8, 2026 updated by: University of Southern California
This study seeks to understand how endometrial cancer patients get medical information about cancer care and their satisfaction with those health-seeking methods.
It also assesses patient interest in using an artificial intelligence educational resource.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine how patients with endometrial cancer in the LA General Medical Center gynecologic oncology clinic currently obtain information about endometrial cancer care, and patient satisfaction with those health-seeking methods.
OUTLINE: This is an observational study.
Patients complete a survey on study.
Study Type
Observational
Enrollment (Estimated)
48
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90033
- USC / Norris Comprehensive Cancer Center
-
Contact:
- Xiaoyue M. Guo
- Email: xiaoyue.guo@med.usc.edu
-
Principal Investigator:
- Xiaoyue M. Guo
-
Los Angeles, California, United States, 90033
- Los Angeles General Medical Center
-
Contact:
- Xiaoyue M. Guo
- Email: xiaoyue.guo@med.usc.edu
-
Principal Investigator:
- Xiaoyue M. Guo
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients of the LA General gynecologic oncology clinic with a biopsy-proven diagnosis of endometrial cancer.
Description
Inclusion Criteria:
- Patient of the LA General gynecologic oncology clinic
- Age 18 years or older
- Biopsy-proven diagnosis of endometrial cancer
- Willing and able to provide informed consent
Exclusion Criteria:
- Patients who do not speak English or Spanish
- Patients who do not provide informed consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Observational
Patients complete a survey on study.
|
Non-interventional study
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Current medical resources used by patients and perceived relative importance of those resources
Time Frame: Up to 1 year
|
Will be analyzed using a qualitative description with a potential subgroup analysis of current medical resources based on various demographic information.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Demographics of patients
Time Frame: Up to 1 year
|
Will be analyzed using a qualitative description of the demographics of patients involved in this specific study.
|
Up to 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Xiaoyue M Guo, University of Southern California
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 31, 2026
Primary Completion (Estimated)
June 9, 2027
Study Completion (Estimated)
June 9, 2028
Study Registration Dates
First Submitted
November 20, 2025
First Submitted That Met QC Criteria
December 10, 2025
First Posted (Actual)
December 12, 2025
Study Record Updates
Last Update Posted (Actual)
May 12, 2026
Last Update Submitted That Met QC Criteria
May 8, 2026
Last Verified
May 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 5U-25-1 (Other Identifier: USC / Norris Comprehensive Cancer Center)
- P30CA014089 (U.S. NIH Grant/Contract)
- NCI-2025-03594 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- UP-25-00331
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Carcinoma
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnAtypical Endometrial Hyperplasia | Recurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IA Endometrial Carcinoma | Stage IB Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage... and other conditions
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Stage IIIA Endometrial Carcinoma | Stage IIIB Endometrial Carcinoma | Stage IIIC Endometrial Carcinoma | Stage IVA Endometrial Carcinoma | Stage IVB Endometrial... and other conditionsCanada
-
Case Comprehensive Cancer CenterTerminatedStage IV Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage II Endometrial Carcinoma | Stage I Endometrial CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Endometrial Clear Cell Carcinoma | Endometrial Papillary Serous Carcinoma | Endometrial Adenosquamous Cell Carcinoma | Endometrial AdenoacanthomaUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Mixed Adenocarcinoma | Endometrial...United States
-
National Cancer Institute (NCI)NRG Oncology; Canadian Cancer Trials GroupActive, not recruitingEndometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditionsUnited States, Canada, Puerto Rico, Japan, South Korea
-
Memorial Sloan Kettering Cancer CenterRecruitingEndometrial Cancer | Endometrial Carcinoma | Stage III Endometrial Carcinoma | Stage III Endometrial Cancer | Endometrial Carcinoma Stage IIIUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedRecurrent Uterine Corpus Carcinoma | Endometrial Clear Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Endometrial Adenocarcinoma | Endometrial Transitional Cell Carcinoma | Endometrial Mucinous Adenocarcinoma | Endometrial Squamous Cell Carcinoma | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal NeoplasmUnited States
-
National Cancer Institute (NCI)Gynecologic Oncology GroupCompletedRecurrent Endometrial Carcinoma | Endometrial Adenocarcinoma | Stage IV Endometrial CarcinomaUnited States
Clinical Trials on Non-Interventional Study
-
Ohio State University Comprehensive Cancer CenterCompletedHeavy Metal Exposure From VapingUnited States
-
Portsmouth Hospitals NHS TrustArdia Digital Health LtdNot yet recruitingChronic Kidney Disease
-
Mayo ClinicRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Ohio State University Comprehensive Cancer CenterLilly FoundationRecruitingAnatomic Stage IV Breast Cancer AJCC v8 | Advanced Breast Carcinoma | Metastatic Breast CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Enrolling by invitationBarrett Esophagus | Esophageal AdenocarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Merck Sharp & Dohme LLCRecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Roswell Park Cancer InstituteRecruitingCigarette Smoking-Related CarcinomaUnited States
-
Children's Oncology GroupNot yet recruitingChildhood Hematopoietic and Lymphatic System Neoplasm | Childhood Malignant Solid Neoplasm
-
Ohio State University Comprehensive Cancer CenterAmerican Association for Cancer ResearchRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Breast Carcinoma | Hormone Receptor-Positive Breast CarcinomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States